Recombinant endotoxin neutralizing protein improves survival from Escherichia coli sepsis in rats
- 1 January 1995
- journal article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 23 (1) , 92-98
- https://doi.org/10.1097/00003246-199501000-00017
Abstract
A recombinant endotoxin neutralizing protein was evaluated for its ability to ameliorate the effects of Escherichia coli sepsis in rats. Prospective, controlled animal trial. Hospital animal research laboratory. Wistar rats, treated with gentamicin 1 hr after challenge with intraperitoneal E. coli O18ac. The animals received a recombinant endotoxin neutralizing protein, in doses of 5, 25, or 50 mg/kg, either 30 or 60 mins after challenge; controls received saline. Geometric mean serum endotoxin concentrations in endotoxin neutralizing protein-treated animals did not differ from control animals. Tumor necrosis factor concentrations in animals treated with endotoxin neutralizing protein 30 mins after challenge were significantly lower than controls. Animals treated with 25 or 50 mg/kg of endotoxin neutralizing protein 30 mins after E. coli challenge had significant improvements in survival compared with controls. Animals treated with 50 mg/kg of endotoxin neutralizing protein 60 mins after E. coli challenge had significant improvements in survival compared with controls. Endotoxin neutralizing protein significantly reduces mortality from Gram-negative sepsis in an antibiotic-treatment model of E. coli peritonitis and bacteremia in rats, mediated by a neutralization of the biological effects of endotoxin.Keywords
This publication has 16 references indexed in Scilit:
- Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challengeCritical Care Medicine, 1994
- Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5Critical Care Medicine, 1994
- Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide.The Journal of Experimental Medicine, 1993
- The Pathogenesis of SepsisAnnals of Internal Medicine, 1991
- A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative SepsisJAMA, 1991
- Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against EndotoxinNew England Journal of Medicine, 1991
- Neonatal Susceptibility and Immunity to Major Bacterial PathogensClinical Infectious Diseases, 1990
- Septic shock in childrenThe Pediatric Infectious Disease Journal, 1990
- Trends in mortality in children hospitalized with meningococcal infections, 1957 to 1987The Pediatric Infectious Disease Journal, 1989
- anti-LPS factor: An anticoagulant which inhibits the endotoxin-mediated activation of coagulation systemBiochemical and Biophysical Research Communications, 1982